Clinical trial
Comparison of Mean Change in Macular Thickness Between Intravitreal Bevacizumab and Posterior Sub-Tenon Triamcinolone Acetonide for Diabetic Macular Edema
NCT07933250 is registered in ClinicalTrials.gov with Muhammad Aamir Latif as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Comparison of Mean Change in Macular Thickness Between Intravitreal Bevacizumab and Posterior Sub-Tenon Triamcinolone Acetonide for Diabetic Macular Edema
- Lead sponsor
- Muhammad Aamir Latif
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- October 1, 2025
- Completion date
- June 30, 2026
- Enrollment
- 46 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
diabetic macular edema
Arms
As registered; 2 arms.
-
Bevacizumab-Group
Patients received an intravitreal injection of bevacizumab 1.25 mg/0.05 mL through the pars plana 3.5-4 mm posterior to the limbus under local anesthesia.
-
Triamcinolone acetonide-Group
Patients received a posterior sub-Tenon injection of triamcinolone acetonide 1.25 mg under aseptic conditions. The triamcinolone was drawn into a 1-mL syringe and administered using a 26-gauge, 5/8-inch sharp-tipped needle, which was advanced to facilitate deposition within the posterior sub-Tenon space.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Central Macular Thickness
Change in CMT, measured in micrometers (μm), was calculated as baseline CMT minus CMT measured one month after treatment. A positive value indicated a reduction in CMT, whereas a negative value indicated an increase in CMT.
Lead sponsor's other trials
Muhammad Aamir Latif, most recent start first.
+52 more trials See the organization page